ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2423

Mir-27b As Biomarker and Regulator Of IL-6R Pathway In Resistant Rheumatoid Arthritis Monocyte

Marina Frleta1, Ashleigh-Ann Rainey2, Derek S. Gilchrist3, Lynn Crawford3, Derek Baxter3, Mariola Kurowska-Stolarska4 and Iain B. McInnes2, 1Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, 2Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 3Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 4Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: cytokines, inflammation and synovitis, MicroRNA, Pathophysiology

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Human Etiology and Pathogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Whereas molecular mechanisms mediating treatment responses to biologic DMARDS in Rheumatoid Arthritis (RA) are emerging, those pathways that subserve treatment resistance are poorly explored. MicroRNAs (miRs) post-transcriptionally regulate different elements of given signal pathways, and as such capture a ‘snapshot’ of the cell state. We previously assembled a cross-sectional cohort of RA patients with distinct therapy response characteristics including rapid sustained response to conventional (c)DMARD, cDMARD failure and recurrent DMARD (conventional and biologic) resistance. We sought herein to identify dysregulated miR species in therapy resistant patients.

Methods:

Peripheral blood (PB) CD14+ monocytes were isolated from three groups of RA patients meeting ACR 2010 criteria: good responders to cDMARD (n=20), failing cDMARDs (n=17) or resistant to biologic agents (n=30). Comparative samples from age-matched healthy volunteers (n=23) were obtained. Candidate miR profiling (based on cytokine receptor targeting miRs) was performed using real-time quantitative PCR. Potential miR-27a/b targets were identified using TargetScan with transcriptional pathway analysis data from PB RA CD14+ cells and functionally validated by Luciferase reporter assay. THP-1 cells were transfected with control or miRNA-27a/b antagomiR and membrane IL-6R expression evaluated by flow cytometry.

Results:

We identified that miR-27b was significantly down-regulated in sorted CD14+ monocytes obtained from cDMARD failure and biologic treatment resistant, compared to cells from patients responding well to cDMARD and HV (p<0.03). Elevated levels of serum IL-6 were evident in both therapy resistant groups (p<0.001). TargetScan identified several potential miR-27 targets in the IL-6R signal pathway, including soluble and membrane bound variants of IL-6 receptor (IL-6R). Both IL-6R isoforms were confirmed as direct targets of miR-27a/b by luciferase reporter assay. Inhibition of endogenous miR-27a/b via antagomiR in THP-1 cells (myeloid line) significantly increased surface levels of Il-6R (p=0.05, n=4), demonstrating that miR-27a/b actively regulates membrane IL-6R expression.

Conclusion:

Together our data uncover a previously unrecognized miR-27:IL-6R pathway interaction that operates particularly in monocytes of RA patients with active or treatment refractory disease. Our study thereby identifies a potential new biomarker and functional mechanism associated with disease chronicity.


Disclosure:

M. Frleta,
None;

A. A. Rainey,
None;

D. S. Gilchrist,
None;

L. Crawford,
None;

D. Baxter,

Roche Pharmaceuticals,

2;

M. Kurowska-Stolarska,

Roche Pharmaceuticals,

2;

I. B. McInnes,

Roche Pharmaceuticals,

2.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mir-27b-as-biomarker-and-regulator-of-il-6r-pathway-in-resistant-rheumatoid-arthritis-monocyte/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology